Brief: Initiator Pharma Gets UK CTA Approval For Phase 2a Study
Nov 3 (Reuters) - Initiator Pharma A/S INIT.ST: RECEIVES UK CTA APPROVAL TO INITIATE PHASE 2A STUDY IN VULVODYNIA FIRST PATIENTS EXPECTED TO BE ENROLLED IN Q4 2025 Source text: ID:nMFN9fd3Lg Further company coverage: INIT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Initiator Pharma A/S
See all newsBrief: Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
Brief: Initiator Pharma To Fully Prioritize Pudafensine
Brief: Initiator Pharma Reports Q4 Net Revenue Of DKK 0.00
Brief: Initiator Pharma Q4 Operating Loss Widens To DKK 7 Mln
Brief: Initiator Pharma Granted European Patent For Pudafensine in FSD